Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Belite Bio, Inc - American Depositary Shares
(NQ:
BLTE
)
153.36
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
153.36
Bid (Size)
152.85 (200)
Ask (Size)
165.56 (100)
Prev. Close
153.36
Today's Range
153.36 - 153.36
52wk Range
60.00 - 200.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases
↗
July 22, 2026
Panelists at the H.C. Wainwright Sixth Annual Ophthalmology Virtual Conference said investigational therapies for inherited retinal disorders could begin to reshape treatment options for Stargardt...
Via
MarketBeat
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
July 20, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Performance
YTD
-3.7%
-3.7%
1 Month
+3.1%
+3.1%
3 Month
-5.9%
-5.9%
6 Month
-5.6%
-5.6%
1 Year
+147.2%
+147.2%
More News
Read More
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
July 15, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Inc - ADR (NASDAQ:BLTE) Reports Narrower-Than-Expected Q4 Loss, NDA Submission on Track for 2026
↗
March 02, 2026
Via
Chartmill
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
↗
July 09, 2026
Via
MarketBeat
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
July 06, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
July 06, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
June 12, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 02, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Q1 Earnings Call Highlights
↗
May 20, 2026
Via
MarketBeat
Topics
Earnings
Belite Bio (BLTE) Q1 2026 Earnings Transcript
↗
May 20, 2026
Via
The Motley Fool
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
May 20, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
May 18, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
May 15, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
May 13, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
April 29, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
April 27, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
April 23, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio to Participate in Four Upcoming Investor Conferences
April 23, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
April 22, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
April 21, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 31, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript
↗
March 03, 2026
Via
The Motley Fool
Topics
Earnings
Belite Bio to Participate in the Leerink Global Healthcare Conference
March 02, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 02, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Frequently Asked Questions
Is Belite Bio, Inc - American Depositary Shares publicly traded?
Yes, Belite Bio, Inc - American Depositary Shares is publicly traded.
What exchange does Belite Bio, Inc - American Depositary Shares trade on?
Belite Bio, Inc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Belite Bio, Inc - American Depositary Shares?
The ticker symbol for Belite Bio, Inc - American Depositary Shares is BLTE on the Nasdaq Stock Market
What is the current price of Belite Bio, Inc - American Depositary Shares?
The current price of Belite Bio, Inc - American Depositary Shares is 153.36
When was Belite Bio, Inc - American Depositary Shares last traded?
The last trade of Belite Bio, Inc - American Depositary Shares was at 07/24/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
